Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • Advanced therapies
  • Virology
  • Bacteriology
  • Biotherapeutics
  • Analytical sciences
  • Diagnostics
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Virology  /  
  • Influenza Resource Centre  /  
  • Full reagent update

Reagent update

Current availability from MHRA of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2025-26 northern hemisphere season and in the 2025 southern hemisphere season (see below for pricing information)

More information can be found in the Influenza Resource Centre pages

Update 17 March 2025

Candidate influenza viruses for use in the northern hemisphere 2025-261 and southern hemisphere 20252

Candidate influenza vaccine viruses

NIBSC code

H1N1

 

A/Victoria/4897/2022

23/252

IVR-238 reassortant derived from A/Victoria/4897/2022

23/250

A/West Virginia/30/2022

23/122

A/Wisconsin/67/2022

23/120

A/Norway/31694/2022

22/312

NIB-133 reassortant derived from A/Norway/31694/2022

23/112

NIB-134 reassortant derived from A/Catalonia/NSVH161512065/2022

23/126

CNIC-2301 reassortant derived from A/Sichuan-Qingyang/SWL1148/2023

23/214

H3N2

 

A/Croatia/10136RV/2023

24/160

NIB-146 reassortant derived from A/Croatia/10136RV/2023

24/158

NYMCX-425A reassortant derived from A/Croatia/10136RV/2023

24/162

A/District of Columbia/27/2023

24/166

NIB-142 reassortant derived from A/District of Columbia/27/2023

24/164

B (Victoria lineage)

 

B/Austria/1359417/2021

23/228

BVR-26 reassortant derived from B/Austria/1359417/2021

22/204

BX-107A reassortant derived from B/Austria/1359417/2021

22/134

B/Michigan/01/2021

21/244

B/Singapore/WUH4618/2021

21/242

B/Guangdong-Zhenjiang/1516/2021

21/388

1 Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season

2 Recommendations announced for influenza vaccine composition for the 2025 southern hemisphere influenza season

Access To B/Yamagata lineage viruses is currently restricted.

Please contact Othmar.Engelhardt@mhra.gov.uk and Jason.Long@mhra.gov.uk

SRD reagents for use in the northern hemisphere 2025-261 and southern hemisphere 20252

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

A/Victoria/4897/2022 (IVR-238) antigen

22/320

A/Georgia/12/2022 (CVR-167) (cell derived) antigen

24/198

A/Victoria/4897/2022 - like antiserum

23/278 

H3N2

 

A/Croatia/10136RV/2023 (NYMC X-425A)) antigen

24/174

A/Croatia/10136RV/2023– like antiserum

24/176

B (Victoria lineage)

 

B/Austria/1359417/2021 (BVR-26) antigen

24/180

B/Michigan/01/2021 antigen

21/330

B/Singapore/WUH4618/2021 (cell derived) antigen

23/268

B/Austria/1359417/2021 - like antiserum

24/118

B (Yamagata lineage)

 

B/Phuket/3073/2013 antigen

24/182

B/Utah/9/2014 (cell derived) antigen

15/100

B/Singapore/INFTT-16-0610/2016 (cell derived) antigen

19/308

B/Phuket/3073/2013 - like antiserum

22/132

1 Recommendations announced for influenza vaccine composition for the 2025–2026 northern hemisphere influenza season

2 Recommendations announced for influenza vaccine composition for the 2025 southern hemisphere influenza season

Neuraminidase reagents in use

Neuraminidase reagents

NIBSC code

N1

 

NA antiserum prepared from A/California/7/2009

10/218

NA antiserum prepared from A/New Caledonia/20/99

04/230

NA antiserum prepared from A/Victoria/4897/2022

23/208

N2

 

NA antiserum prepared from A/Victoria/361/2011

14/144

NA antiserum prepared from A/South Australia/34/2019

19/320

B

 

NA antiserum prepared from B/Jiangsu/10/2003

04/228

NA antiserum prepared from B/Malaysia/2506/2004

05/252

NA antiserum prepared from B/Phuket/3073/2013

21/322

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to a handling fee as stated on the product information page, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.

Calibration of Reagents for Influenza vaccine standardisation

Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:

Essential Regulatory Laboratories (ERL)


  • Medicines and Healthcare products Regulatory Agency (MHRA), UK
  • Center for Biologics Evaluation and Research (CBER), USA
  • National Institute for Infectious Disease (NIID), Japan
  • Therapeutic Goods Administration (TGA), Australia
Key staff

Othmar Engelhardt, Principal Scientist
Jason Long, Principal Scientist
Francesco Gubinelli, Senior Scientist
Basma Bahsoun, Scientist
Victoria Bailey, Scientist
Sitara Dubey, Scientist
Elli Elenoglou, Scientist
Kajetan Rakowski, Scientist

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap